Answers are grounded in this paper and cite their sources.
Oral submucous fibrosis (OSF) is a refractory oral mucosal disease with malignant potential, characterized by the activation of myofibroblasts (MFBs), submucosal collagen deposition, and oxidative stress induced by areca nut chewing. Crucially, the excessive collagen in the submucosal area not only defines the pathology but also creates a recalcitrant barrier impeding drug penetration and compromising therapeutic efficacy. To breach this barrier, we developed a multifunctional nanodrill hydrogel system (LC-CC/PT) based on a “break and block” strategy. Specifically, the LC-CC nanodrill with collagen-targeting, penetrating, and degrading abilities was fabricated to deliver the antifibrotic curcumin into the fibrotic center. The LC-CC nanodrill was further incorporated with a thermosensitive Pluronic F-127 (PF127)/tannic acid (PT) hydrogel to improve its injectability and local retention. Mechanistically, LC-CC/PT effectively dismantles the pathological collagen barrier while simultaneously suppressing the fibroblast-to-myofibroblast (FB-to-MFB) transition and collagen formation, thus executing a “break and block” antifibrotic cascade. Furthermore, LC-CC/PT revealed multi-hierarchical ROS scavenging ability against extracellular, intracellular, and mitochondrial ROS to restore the redox homeostasis and alleviate cellular senescence in OSF. In vivo administration of LC-CC/PT demonstrated superior antifibrotic efficiency in a rat OSF model. Overall, this study offers a novel paradigm to modulate pathological collagen dynamics, providing a promising and translatable therapeutic strategy for OSF and other recalcitrant fibrotic disorders.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: